The ATR inhibitor ceralasertib enhances the efficacy of PARP inhibitors in homologous recombination deficient (HRD) ovarian cancer by inhibiting the DNA damage response (DDR) pathway (NCT03462342) (124–135). This evidence concerns the gene PARP1 and ovarian carcinoma.